Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
SOUTH SAN FRANCISCO - Vaxart, Inc. (OTCQX:VXRT), currently trading at $0.37 with a market capitalization of $82.16 million, announced it will host a virtual stockholder fireside chat on Wednesday, August 20, 2025, where management will address questions about the company’s proposed reverse stock split and efforts to regain Nasdaq compliance. According to InvestingPro data, the stock has declined over 50% in the past six months.
Leading proxy advisory firms Institutional Shareholder Services (ISS) and Glass Lewis have both recommended stockholders support the reverse stock split proposal, according to the company’s press release statement.
"Our leadership team is excited for this opportunity to connect with our stockholders directly," said Steven Lo, Chief Executive Officer of Vaxart. "This fireside chat is a chance for us to answer many of the frequently asked questions from our stockholders, particularly around the rationale for a reverse stock split and the need to regain Nasdaq compliance."
The virtual event will begin at 4:30 p.m. ET / 1:30 p.m. PT. Stockholders may submit questions in advance via email or through the webcast portal.
Vaxart, a clinical-stage biotechnology company with an EBITDA of -$48.24 million in the last twelve months, develops oral recombinant vaccines using its proprietary delivery platform. The company’s current development programs include pill vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus. InvestingPro subscribers can access 8 additional key insights about Vaxart’s financial health and growth prospects through the comprehensive Pro Research Report.
The company is urging all stockholders of record as of July 29, 2025, who have not yet voted to do so by 11:59 p.m. Eastern Time on September 4, 2025.
In other recent news, Vaxart Inc. reported its Q2 2025 earnings, showcasing a notable increase in revenue to $39.7 million. This growth was primarily fueled by a contract with the Biomedical Advanced Research and Development Authority (BARDA). Despite the revenue surge, Vaxart’s earnings per share (EPS) reported a loss of $0.07, which was an improvement over the anticipated loss of $0.09. These financial results reflect mixed investor sentiment, as indicated by subsequent stock trading fluctuations. The earnings announcement did not include any updates on mergers or acquisitions. There were no analyst upgrades or downgrades reported in conjunction with the earnings release. The company’s financial performance highlights the impact of strategic contracts on revenue, even as challenges in profitability persist.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.